Journal of Clinical Endocrinology & Metabolism, Vol 81, 449-452, Copyright © 1996 by Endocrine Society

ARTICLES

Interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptor inhibit IL-1-induced glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves' ophthalmopathy

GH Tan, CM Dutton and RS Bahn
Division of Endocrinology/Metabolism, Mayo Clinic/Mayo Foundation, Rochester, Minnesota 55905, USA.

An accumulation of glycosaminoglycans (GAG) is a feature characteristic of orbital connective tissues from patients with Graves' ophthalmopathy (GO) that leads directly to the clinical expressions of the disease. Interleukin-1 (IL-1), produced by macrophages and fibroblasts within the diseased orbit, stimulates GAG synthesis by orbital fibroblasts. We designed the current study to determine whether particular agents might block this effect and thus be useful in the treatment of GO. Orbital fibroblast cultures were grown to confluence and incubated for 48 h with IL-1 (1-10 U/mL) alone or IL-1 (10 U/mL) in combination with IL-1 receptor antagonist (IL-1ra; 1-40 ng/mL) or soluble IL-1 receptor (sIL- 1R; 0.25-10 micrograms/mL). Cells were labeled with [3H]glucosamine and processed for GAG quantitation. The addition of IL-1 alone stimulated GAG synthesis by 73-176% (mean, 104%; P < 0.05). Significant inhibition of IL-1-stimulated GAG synthesis was observed after treatment of normal fibroblasts with IL-1ra at a concentration of 5 ng/mL (12.5-fold molar excess; mean, 33%; P < 0.05); essentially complete inhibition was achieved at 40 ng/mL (100-fold molar excess; mean, 86%; P < 0.05). Significant inhibition of GAG synthesis by sIL-1R was observed at a concentration of 0.5 microgram/mL (720-fold molar excess; mean, 79%; P < 0.05), and inhibition was essentially complete at 1 microgram/mL (1440-fold molar excess; mean, 89%; P < 0.05). IL-1ra and sIL-1R are potent inhibitors of IL-1-induced GAG production by cultured human orbital fibroblasts. Our results suggest that these two compounds, shown in early trials to be safe when administered parenterally, may be useful in the prevention or treatment of GO.

This article has been cited by other articles:

				T J Cawood, P Moriarty, C O'Farrelly, and D O'Shea The effects of tumour necrosis factor-{alpha} and interleukin1 on an in vitro model of thyroid-associated ophthalmopathy; contrasting effects on adipogenesis Eur. J. Endocrinol., September 1, 2006; 155(3): 395 - 403. [Abstract] [Full Text] [PDF]

				L. Bartalena, A. Pinchera, and C. Marcocci Management of Graves' Ophthalmopathy: Reality and Perspectives Endocr. Rev., April 1, 2000; 21(2): 168 - 199. [Abstract] [Full Text]

				T. Mühlberg, W. Joba, C. Spitzweg, H.-D. Schworm, H.-J. Heberling, and A. E. Heufelder Interleukin-1 Receptor Antagonist Ribonucleic Acid and Protein Expression by Cultured Graves' and Normal Orbital Fibroblasts Is Differentially Modulated by Dexamethasone and Irradiation J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 734 - 742. [Abstract] [Full Text]

				G. J. Kahaly, H.-P. Rösler, S. Pitz, and G. Hommel Low- Versus High-Dose Radiotherapy for Graves' Ophthalmopathy: A Randomized, Single Blind Trial J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 102 - 108. [Abstract] [Full Text]

				C. Hansen, R. Rouhi, G. Förster, and G. J. Kahaly Increased Sulfatation of Orbital Glycosaminoglycans in Graves' Ophthalmopathy J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1409 - 1413. [Abstract] [Full Text]

				L. C. Hofbauer, T. Muhlberg, A. Konig, G. Heufelder, H.-D. Schworm, and A. E. Heufelder Soluble Interleukin-1 Receptor Antagonist Serum Levels in Smokers and Nonsmokers with Graves' Ophthalmopathy Undergoing Orbital Radiotherapy J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2244 - 2247. [Abstract] [Full Text] [PDF]